In a subgroup of patients, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a hyperinflammatory response that leads to acute respiratory distress syndrome.[@bib1] SARS coronaviruses have been shown to trigger the inflammasome and the release of interleukin-1β (IL-1β).[@bib2]

We did a retrospective analysis of ten patients (nine white men and one white woman) with confirmed SARS-CoV-2 infection, bilateral pneumonia, hyperinflammation (defined as serum C-reactive protein ≥50 mg/L), and respiratory failure (requiring supplemental oxygen without invasive ventilation). These patients were treated with canakinumab, a human monoclonal antibody against IL-1β, administered subcutaneously in a single 300 mg dose, in April, 2020, at the Infectious Disease Clinic of SS. Annunziata Hospital in Chieti, Italy ([appendix pp 1--8](#sec1){ref-type="sec"}). All patients also received hydroxychloroquine (200 mg twice daily) and lopinavir--ritonavir (400 mg twice daily of lopinavir and 100 mg twice daily of ritonavir). The patients provided written informed consent for the off-label use of the drugs. The patients\' baseline characteristics can be found in the [appendix (pp 1, 4)](#sec1){ref-type="sec"}.

Canakinumab was well tolerated, with no recorded injection site reactions or systemic adverse events. Canakinumab administration was associated with a rapid and significant reduction in serum C-reactive protein at day 1 and day 3 and an improvement in oxygenation, with the PaO2:FiO2 ratio increasing between baseline and day 3 and day 7 after treatment ([appendix pp 2, 7--8](#sec1){ref-type="sec"}). At 45 days after hospitalisation, all ten patients were alive and discharged from hospital without physical limitations caused by COVID-19 or the need for oxygen therapy ([appendix p 3](#sec1){ref-type="sec"}). Notably, none of the patients developed neutropenia or bacterial sepsis.

For an indirect comparison, we selected the first ten patients with confirmed SARS-CoV-2 infection, bilateral pneumonia, hyperinflammation, and respiratory failure (requiring supplemental oxygen without invasive ventilation) who were hospitalised at our centre in March, 2020. These patients received hydroxychloroquine and lopinavir--ritonavir, but not canakinumab. By contrast to the patients treated with canakinumab, the patients not treated with canakinumab showed slower improvements in serum C-reactive protein and PaO~2~:FiO~2~ ratio ([appendix pp 5, 8](#sec1){ref-type="sec"}). At 45 days after hospitalisation, one patient had died, nine patients had been discharged from hospital, and one of the nine discharged patients required oxygen therapy ([appendix p 6](#sec1){ref-type="sec"}).

To our knowledge, these data, although preliminary, are the first to describe the use of canakinumab to treat patients with COVID-19. Canakinumab is an IL-1 blocker approved for the treatment of juvenile rheumatoid arthritis and other chronic autoinflammatory syndromes. Cavalli and colleagues[@bib3] reported on the efficacy of another IL-1 blocker, intravenous anakinra (5 mg/kg twice daily), which also rapidly reduced serum C-reactive protein, improved oxygenation, and, when compared with a matched cohort, was associated with improved survival. Our observations add further evidence to support the central role of IL-1β in the pathophysiology of COVID-19. Although anakinra functions as a receptor antagonist that blocks the activity of both IL-1β and IL-1α, canakinumab selectively blocks the IL-1β that is generated within the inflammasome.[@bib4] The rapid improvement in serum inflammatory biomarkers after the administration of canakinumab therefore implicates the IL-1β inflammasome pathway in the pathophysiology of COVID-19.

Notwithstanding the many limitations of these initial data, such as the small sample size and the absence of a random comparison, these data represent the first available description of the use of canakinumab to treat COVID-19 and show a rather favourable safety and efficacy profile that would be considered encouraging if compared with other published cohort studies.[@bib3], [@bib4] Canakinumab is already commercially available. When tested in patients with cardiovascular disease, a group that is at a particularly high risk for COVID-19-related mortality, canakinumab significantly reduced the incidence of atherothrombotic events and heart failure exacerbations, which is another potential benefit.[@bib5]

In conclusion, in ten hospitalised adult patients with COVID-19, bilateral pneumonia, hyperinflammation, and respiratory failure who did not require mechanical ventilation, 300 mg of subcutaneous canakinumab was safe, well tolerated, and associated with a rapid reduction in the systemic inflammatory response and an improvement in oxygenation.
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